EP Patent

EP4382093A1 — Oral suspensions comprising capecitabine

Assigned to A Fine House SA · Expires 2024-06-12 · 2y expired

What this patent protects

Oral pharmaceutical suspension comprising capecitabine and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides and at least one suspending agent.

USPTO Abstract

Oral pharmaceutical suspension comprising capecitabine and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides and at least one suspending agent.

Drugs covered by this patent

givinostat-hydrochloride (GIVINOSTAT HYDROCHLORIDE)

Patent Metadata

Patent number: EP4382093A1
Jurisdiction: EP
Classification: —
Expires: 2024-06-12
Drug substance claim: No
Drug product claim: No
Assignee: A Fine House SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.